Rafaèle TORDJMAN

Bio

Dr. Rafaèle Tordjman, MD PhD, is a physician and researcher in haemato-oncology, a former medical resident at the Paris Hospitals, and a former researcher at INSERM. She has been investing in the life sciences sector for more than 20 years. After five years working at the Paris University Hospitals as a medical doctor specialising in internal medicine and clinical hematology, she presented her doctoral thesis on Haematopoiesis and Angiogenesis, which she obtained in 2000. She then completed her post-doctoral work in immunology at INSERM, Cochin Hospital, and published in Nature Immunology among others. In 2002, she also completed a management training course at INSEAD. Before founding Jeito Capital, Rafaèle Tordjman spent 17 years at Sofinnova Partners, a venture capital firm, where she started aas n analyst and became co-leader and partner with €1.5 billion in assets under management. In 2018, Dr. Tordjman founded Jeito Capital, independent investment firm dedicated to supporting Biopharma development, with the goal of establishing a continuous financing model and investing in the next generation of leaders in medical innovation. With €1.6 billion in assets under management, Jeito Capital is the largest independent firm in Europe dedicated to Biopharma. Jeito has invested across a broad range of therapeutic areas, including oncology and immuno-oncology, autoimmune and inflammatory diseases, ophthalmology, cardiology, neuromuscular and neurometabolic diseases, obesity, reproductive medicine, and women’s health. To engage more women in the life sciences industry, in 2010 Dr. Tordjman founded the association W.I.T.H. (Women Innovating Together in Healthcare) that now has a global membership of more than 500 women representing the full chain of medical innovation. In September 2020, Dr. Tordjman was awarded Chevalier de la Légion d’Honneur, France’s highest distinction. In July 2021, Dr. Tordjman was appointed by Agnès Pannier-Runacher, Minister Delegate for Industry and Franck Riester, Minister Delegate for Foreign Trade and Economic Attractiveness, under the high patronage of President Emmanuel Macron to promote the French Biopharma and healthcare innovation ecosystem among leading international players. Dr. Tordjman has also been nominated in the 2023 Forbes “50 Over 50” selection across Europe, Middle East And Africa, spotlighting successful women who are reaching new heights in their industries